AN2 Therapeutics, Inc. (NASDAQ: ANTX) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT AN2 THERAPEUTICS, INC.

AN2 Therapeutics, Inc. (NASDAQ: ANTX)
Listen to this Section


$3.93
-0.2400 ( -5.76% ) 63.2K

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Market Data


Open $3.93
Previous Close $4.17
Volume 63.2K
Market Cap $151.27M
Day Range $3.93 - $4.19
52 Week Range $1.00 - $6.91
Shares Outstanding 36.02M
Change % -5.76%
Net Change ▼ -0.2400
Insider Ownership -0.18%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2022
CountryUnited States
UnderwriterTD Cowen, Leerink Partners, Evercore ISI, Oppenheimer & Co., more

Insider Ownership Transactions

Total Amount Purchased: -1,219,102.00

Date Type Amount Purchased Purchaser
2024-01-11 Sale -2417.00 Krause Kevin Michael
2024-01-04 Sale -2583.00 Krause Kevin Michael
2024-01-04 Sale -2777.00 Easom Eric
2023-11-16 Sale -1522.00 Aziz Kabeer
2023-11-16 Sale -1522.00 Adjuvant Global Health Technology Fund, L.P.
2023-10-03 Sale -83337.00 Aziz Kabeer
2023-10-03 Sale -83337.00 Adjuvant Global Health Technology Fund, L.P.
2023-09-29 Sale -707.00 Adjuvant Global Health Technology Fund, L.P.
2023-09-29 Sale -707.00 Aziz Kabeer
2023-09-15 Sale -336.00 Aziz Kabeer

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 60 Nov 12, 2025
8-k 8K-related 11 Nov 12, 2025
4 Insider transactions 1 Nov 06, 2025
4 Insider transactions 1 Nov 06, 2025
4 Insider transactions 1 Oct 14, 2025
4 Insider transactions 1 Oct 14, 2025
4 Insider transactions 1 Oct 14, 2025
8-k 8K-related 11 Aug 12, 2025
10-q Quarterly Reports 61 Aug 12, 2025
4 Insider transactions 1 Jul 11, 2025

Latest News


× Before browsing our site, please accept our cookies policy